| 1 |
Bersanelli M, Rebuzzi SE, Roviello G, Catalano M, Brunelli M, Rizzo M. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma. Hum Vaccin Immunother 2023;19:2171672. [PMID: 36758960 DOI: 10.1080/21645515.2023.2171672] [Reference Citation Analysis]
|
| 2 |
Kashima S, Braun DA. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urol Clin North Am 2023;50:335-49. [PMID: 36948676 DOI: 10.1016/j.ucl.2023.01.012] [Reference Citation Analysis]
|
| 3 |
Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol 2023;20:133-57. [PMID: 36414800 DOI: 10.1038/s41585-022-00676-0] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 4 |
Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 2023:S2405-4569(23)00048-2. [PMID: 36863962 DOI: 10.1016/j.euf.2023.02.008] [Reference Citation Analysis]
|
| 5 |
Nyman J, Denize T, Bakouny Z, Labaki C, Titchen BM, Bi K, Hari SN, Rosenthal J, Mehta N, Jiang B, Sharma B, Felt K, Umeton R, Braun DA, Rodig S, Choueiri TK, Signoretti S, Van Allen EM. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. bioRxiv 2023:2023. [PMID: 36712053 DOI: 10.1101/2023.01.18.524545] [Reference Citation Analysis]
|
| 6 |
Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J, Shariat SF, Choueiri T, Müller G, McGregor B, Chang SL, Trinh QD, Mossanen M. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. Clin Genitourin Cancer 2023;21:63-8. [PMID: 36517393 DOI: 10.1016/j.clgc.2022.11.015] [Reference Citation Analysis]
|
| 7 |
Boyle JJ, Pfail JL, Lichtbroun BJ, Singer EA. Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments. JCO Precis Oncol 2023;7:e2200407. [PMID: 36724413 DOI: 10.1200/PO.22.00407] [Reference Citation Analysis]
|
| 8 |
Riveros C, Huang E, Ranganathan S, Klaassen Z, Rini B, Wallis CJD, Satkunasivam R. Adjuvant immunotherapy in renal cell carcinoma: a systematic review and meta-analysis. BJU Int 2023. [PMID: 36709462 DOI: 10.1111/bju.15981] [Reference Citation Analysis]
|
| 9 |
Monteiro FSM, Soares A, Rizzo A, Santoni M, Mollica V, Grande E, Massari F. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis. Clin Genitourin Cancer 2023:S1558-7673(23)00025-3. [PMID: 36823017 DOI: 10.1016/j.clgc.2023.01.005] [Reference Citation Analysis]
|
| 10 |
Li Y, Lih TM, Dhanasekaran SM, Mannan R, Chen L, Cieslik M, Wu Y, Lu RJ, Clark DJ, Kołodziejczak I, Hong R, Chen S, Zhao Y, Chugh S, Caravan W, Naser Al Deen N, Hosseini N, Newton CJ, Krug K, Xu Y, Cho KC, Hu Y, Zhang Y, Kumar-Sinha C, Ma W, Calinawan A, Wyczalkowski MA, Wendl MC, Wang Y, Guo S, Zhang C, Le A, Dagar A, Hopkins A, Cho H, Leprevost FDV, Jing X, Teo GC, Liu W, Reimers MA, Pachynski R, Lazar AJ, Chinnaiyan AM, Van Tine BA, Zhang B, Rodland KD, Getz G, Mani DR, Wang P, Chen F, Hostetter G, Thiagarajan M, Linehan WM, Fenyö D, Jewell SD, Omenn GS, Mehra R, Wiznerowicz M, Robles AI, Mesri M, Hiltke T, An E, Rodriguez H, Chan DW, Ricketts CJ, Nesvizhskii AI, Zhang H, Ding L; Clinical Proteomic Tumor Analysis Consortium. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell 2023;41:139-163.e17. [PMID: 36563681 DOI: 10.1016/j.ccell.2022.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
John A, Spain L, Hamid AA. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. Curr Oncol 2023;30:923-37. [PMID: 36661719 DOI: 10.3390/curroncol30010070] [Reference Citation Analysis]
|
| 12 |
Matsukawa T, Doi T, Obayashi K, Sumida K, Fujimoto N, Endo M. ANGPTL8 links inflammation and poor differentiation, which are characteristics of malignant renal cell carcinoma. Cancer Sci 2022. [PMID: 36529524 DOI: 10.1111/cas.15700] [Reference Citation Analysis]
|
| 13 |
Cabanillas G, Montoya-Cerrillo D, Kryvenko ON, Pal SK, Arias-Stella JA 3rd. "Collecting duct carcinoma of the kidney: diagnosis and implications for management". Urol Oncol 2022;40:525-36. [PMID: 34116936 DOI: 10.1016/j.urolonc.2021.04.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 14 |
Cimadamore A, Caliò A, Marandino L, Marletta S, Franzese C, Schips L, Amparore D, Bertolo R, Muselaers S, Erdem S, Ingels A, Pavan N, Pecoraro A, Kara Ö, Roussel E, Carbonara U, Campi R, Marchioni M; EAU-YAU Renal Cancer Working Group. Hot topics in renal cancer pathology: implications for clinical management. Expert Rev Anticancer Ther 2022;22:1275-87. [PMID: 36377655 DOI: 10.1080/14737140.2022.2145952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Yao C, Zhang T, Wu T, Brugarolas J. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. Clin Cancer Res 2022;28:5013-20. [PMID: 35819272 DOI: 10.1158/1078-0432.CCR-21-2372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Grewal R, Choung HYG, Roberts LL, Beane T, Chen L, Gilroy DX, Rappold PM, Le TH. TMEM27 expression and clinical characteristics and survival in clear cell renal cell carcinoma. Acta Oncol 2022;61:1507-11. [PMID: 36369873 DOI: 10.1080/0284186X.2022.2143279] [Reference Citation Analysis]
|
| 17 |
Wang N, Hakimi AA, Chen Y. XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL. Clin Cancer Res 2022;28:4600-2. [PMID: 35984355 DOI: 10.1158/1078-0432.CCR-22-2104] [Reference Citation Analysis]
|
| 18 |
Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
|
| 19 |
Donskov F, Pinto CA, Predoiu R, Fox C, Georgsen JB, Skaarup K, Burcu M, Perini R, Steiniche T. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. Acta Oncologica. [DOI: 10.1080/0284186x.2022.2119100] [Reference Citation Analysis]
|
| 20 |
Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam J, Kassouf W, Mitchell T, Montironi R, O'Brien T, Panebianco V, Scelo G, Shuch B, van Poppel H, Blosser CD, Psutka SP. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol 2022:S0302-2838(22)02609-4. [PMID: 36100483 DOI: 10.1016/j.eururo.2022.08.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Zuo Y, Fu S, Zhao Z, Li Z, Wu Y, Qi T, Zheng J, Du Q, Xu Z, Yu N. Sarcomatoid-associated gene risk index for clear cell renal cell carcinoma. Front Genet 2022;13:985641. [DOI: 10.3389/fgene.2022.985641] [Reference Citation Analysis]
|
| 22 |
Rabinowitz MJ, Esfandiary T, Cheaib J, Patel SH, Alam R, Metcalf M, Enikeev D, Pierorazio PM, Ged YM, Allaf ME, Singla N. Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma. European Urology Open Science 2022;43:28-34. [DOI: 10.1016/j.euros.2022.07.001] [Reference Citation Analysis]
|
| 23 |
Xu W, Anwaier A, Liu W, Wei G, Su J, Tian X, Xia J, Qu Y, Zhao J, Zhang H, Ye D. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma. Front Immunol 2022;13:953721. [DOI: 10.3389/fimmu.2022.953721] [Reference Citation Analysis]
|
| 24 |
Kourtis N, Wang Q, Wang B, Oswald E, Adler C, Cherravuru S, Malahias E, Zhang L, Golubov J, Wei Q, Lemus S, Ni M, Ding Y, Wei Y, Atwal GS, Thurston G, Macdonald LE, Murphy AJ, Dhanik A, Sleeman MA, Tykodi SS, Skokos D. A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma. Nat Cancer 2022;3:885-98. [PMID: 35668194 DOI: 10.1038/s43018-022-00391-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Patel HD, Man A, Koehne EL, Rac G, Aragao AP, Flanigan RC, Gorbonos A, Gupta GN, Woods ME, Picken MM, Quek ML. Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. Urologic Oncology: Seminars and Original Investigations 2022;40:347.e1-347.e8. [DOI: 10.1016/j.urolonc.2022.04.003] [Reference Citation Analysis]
|
| 26 |
Hong Y, Que Y, Hu Y, Shi BY, Zhu J, Wang J, Huang JT, Sun FF, Zhang L, Zhou XK, Lu SY, Zhang YZ. Immune-Related LncRNAs as Prognostic Factors for Pediatric Rhabdoid Tumor of the Kidney. Dis Markers 2022;2022:4752184. [PMID: 35756490 DOI: 10.1155/2022/4752184] [Reference Citation Analysis]
|
| 27 |
Swearson S, Rataan AO, Eliason S, Amendt BA, Zakharia Y, Salem AK, Ho T, Rustum YM. MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets. Int J Mol Sci 2022;23:5604. [PMID: 35628416 DOI: 10.3390/ijms23105604] [Reference Citation Analysis]
|
| 28 |
Li X, Hu D, Li Y, Luo Y, Liang B, Yu K, Xiong W, Zuo D, Wang F. Overexpression of TP53INP2 Promotes Apoptosis in Clear Cell Renal Cell Cancer via Caspase-8/TRAF6 Signaling Pathway. Journal of Immunology Research 2022;2022:1-23. [DOI: 10.1155/2022/1260423] [Reference Citation Analysis]
|
| 29 |
Serzan M, Atkins MB. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. Expert Rev Anticancer Ther 2022. [PMID: 35483033 DOI: 10.1080/14737140.2022.2072300] [Reference Citation Analysis]
|
| 30 |
Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer 2022;10:e004316. [PMID: 35304405 DOI: 10.1136/jitc-2021-004316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 31 |
Beserra AO, Estevan EC, Bezerra SM, Torrezan GT, Ikegami A, Dellê H, Cunha IW, Meira IT, Carraro DM, Lara PN, Zequi SC, Martins VR, Santos TG. Patient-Derived Renal Cell Carcinoma Xenografts Capture Tumor Genetic Profiles and Aggressive Behaviors. KCA 2022. [DOI: 10.3233/kca-210011] [Reference Citation Analysis]
|
| 32 |
Fontes-sousa M, Calvo E. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 33 |
dos Reis AFP, Simão D, Odeny T, Rodrigues C, Fontes-sousa M, Luz RD, Chowdry RP, Welsh SJ, Paller C, Barata PC. A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. KCA 2022. [DOI: 10.3233/kca-210012] [Reference Citation Analysis]
|
| 34 |
Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, West D, Labaki C, Dudani S, Gan CL, Sethunath V, Carvalho FLF, Imamovic A, Ricker C, Vokes NI, Nyman J, Berchuck JE, Park J, Hirsch MS, Haq R, Mary Lee GS, McGregor BA, Chang SL, Feldman AS, Wu CJ, McDermott DF, Heng DYC, Signoretti S, Van Allen EM, Choueiri TK, Viswanathan SR. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep 2022;38:110190. [PMID: 34986355 DOI: 10.1016/j.celrep.2021.110190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 35 |
Rosellini M, Marchetti A, Tassinari E, Nuvola G, Rizzo A, Santoni M, Mollica V, Massari F. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development 2022;7:131-149. [DOI: 10.1080/23808993.2022.2156786] [Reference Citation Analysis]
|
| 36 |
Quhal F, Mori K, Fajkovic H, Remzi M, Shariat SF, Schmidinger M. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Curr Opin Urol 2022;32:61-8. [PMID: 34720102 DOI: 10.1097/MOU.0000000000000940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 37 |
Gulati S, Previtera M, Lara PN. BRCA1-Associated Protein 1 (BAP-1) as a Prognostic and Predictive Biomarker in Clear Cell Renal Cell Carcinoma: A Systematic Review. KCA 2021. [DOI: 10.3233/kca-210006] [Reference Citation Analysis]
|
| 38 |
Elias R, Tcheuyap VT, Kaushik AK, Singla N, Gao M, Reig Torras O, Christie A, Mulgaonkar A, Woolford L, Stevens C, Kettimuthu KP, Pavia-Jimenez A, Boroughs LK, Joyce A, Dakanali M, Notgrass H, Margulis V, Cadeddu JA, Pedrosa I, Williams NS, Sun X, DeBerardinis RJ, Öz OK, Zhong H, Seshagiri S, Modrusan Z, Cantarel BL, Kapur P, Brugarolas J. A renal cell carcinoma tumorgraft platform to advance precision medicine. Cell Rep 2021;37:110055. [PMID: 34818533 DOI: 10.1016/j.celrep.2021.110055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 39 |
Buti S, Bersanelli M, Mazzaschi G, Cattrini C, Brunelli M, Maio MD. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy 2021. [PMID: 34806404 DOI: 10.2217/imt-2021-0157] [Reference Citation Analysis]
|
| 40 |
Gulati S, Vogelzang NJ. Biomarkers in renal cell carcinoma: Are we there yet? Asian J Urol 2021;8:362-75. [PMID: 34765444 DOI: 10.1016/j.ajur.2021.05.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 41 |
Yoshida T, Ohe C, Ikeda J, Atsumi N, Ohsugi H, Sugi M, Higasa K, Saito R, Tsuta K, Matsuda T, Kinoshita H. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. J Immunother Cancer 2021;9:e002922. [PMID: 34580162 DOI: 10.1136/jitc-2021-002922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 42 |
Agaimy A, Hartmann A, Trpkov K, Hes O. Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Semin Diagn Pathol 2021;38:152-62. [PMID: 34579992 DOI: 10.1053/j.semdp.2021.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 43 |
Stone L. Characterizing sarcomatoid and rhabdoid RCC. Nat Rev Urol 2021;18:189. [PMID: 33686289 DOI: 10.1038/s41585-021-00446-4] [Reference Citation Analysis]
|
| 44 |
Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol 2021. [PMID: 34338966 DOI: 10.1007/s11523-021-00828-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 45 |
Tanguay S, Abel EJ, Albigès L, Choueiri T, Bex A, Capitanio U, Tran M, Volpe A, Black PC. B2B: Kidney Cancer Summary. Proceedings from the SIU B2B Uro-Oncology: GU Cancers Triad Virtual Meeting May 21–22, 2021 2021;2:S19-S28. [DOI: 10.48083/scpm5983] [Reference Citation Analysis]
|
| 46 |
Huang X, Liu D, Wang X. Morphological and hemodynamic analysis of the patient-specific renal cell carcinoma models. J Biomech 2021;126:110636. [PMID: 34298292 DOI: 10.1016/j.jbiomech.2021.110636] [Reference Citation Analysis]
|
| 47 |
Yoshida T, Ohe C, Ikeda J, Atsumi N, Saito R, Taniguchi H, Ohsugi H, Sugi M, Tsuta K, Matsuda T, Kinoshita H. Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma. J Pathol Clin Res 2021. [PMID: 34212534 DOI: 10.1002/cjp2.232] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 48 |
Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int J Mol Sci 2021;22:6237. [PMID: 34207825 DOI: 10.3390/ijms22126237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 49 |
Cimadamore A, Rizzo A, Mollica V, Massari F, Lopez-beltran A, Scarpelli M, Cheng L, Santoni M, Montironi R. An update on immunotherapy in uro-oncology. Expert Review of Precision Medicine and Drug Development 2021;6:229-33. [DOI: 10.1080/23808993.2021.1911638] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 50 |
Choueiri TK, Larkin J, Pal S, Motzer RJ, Rini BI, Venugopal B, Alekseev B, Miyake H, Gravis G, Bilen MA, Hariharan S, Chudnovsky A, Ching KA, Mu XJ, Mariani M, Robbins PB, Huang B, di Pietro A, Albiges L. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open 2021;6:100101. [PMID: 33901870 DOI: 10.1016/j.esmoop.2021.100101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
